Effect of 5-Alpha Reductase Inhibitors on Magnetic Resonance Imaging and Prostate Cancer Detection
Biomolecules · 05.02.2024 · 14 (2) · 193
DOI: 10.3390/biom14020193 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomolecules, online erschienen am 05.02.2024. Verfasst von Juan Morote und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Vall d'Hebron Hospital, 08035 Barcelona, Spain. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Cyanoacrylates. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto de Salut Carlos III (SP).
Abstract (Originalsprache)
Concerns exist regarding the effects of 5-alpha reductase inhibitors (5-ARIs) on multipa-rametric magnetic resonance imaging (mpMRI) and clinically significant prostate cancer (csPCa) detection. Our objective is to analyze the effect of 5-ARI on the prostate imaging–reporting and data system (PI-RADS) distribution and csPCa and insignificant PCa (iPCa) detection. Among 2212 men with serum prostate-specific antigen levels of >3.0 ng/mL and/or suspicious digital rectal examinations who underwent mpMRI and targeted and/or systematic biopsies, 120 individuals exposed to 5-ARI treatment for over a year were identified. CsPCa was defined when the grade group (GG) was >2. The overall csPCa and iPCa detection rates were 44.6% and 18.8%, respectively. Since logistic regression revealed independent predictors of PCa, a randomized matched group of 236 individuals was selected for analysis. The PI-RADS distribution was comparable with 5-ARI exposure (p 0.685). The CsPCa detection rates in 5-ARI-naïve men and 5-ARI-exposed men were 52.6% and 47.4%, respectively (p 0.596). IPCa was detected in 37.6 and 62.5%, respectively (p 0.089). The tumor GG distribution based on 5-ARI exposure was similar (p 0.149) to the rates of csPCa and iPCa across the PI-RADS categories. We conclude that exposure to 5-ARI in suspected PCa men did not change the PI-RADS distribution and the csPCa and iPCa detection rates.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Vall d'Hebron Hospital, 08035 Barcelona, Spain.
- Department of Surgery, Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain.
- Department of Urology, Hospital Universitari de Bellvitge, 08907 Hospitalet de Llobregat, Spain.
- Department of Urology, Hospital Universitari Parc Taulí, 08208 Sabadell, Spain.
- Clínica Creu Blanca, 08034 Barcelona, Spain.
- Department of Urology, Hospital Universitari Joan XXIII, 43005 Tarragona, Spain.
ORCID-Profile: Nahuel Paesano, Xavier Ruiz-Plazas, Berta Miró, José M Abascal
Förderung
- Instituto de Salut Carlos III (SP)
Zitieren
APA
Morote, J., Picola, N., Muñoz-Rodriguez, J., Paesano, N., Ruiz-Plazas, X., Muñoz-Rivero, M. V., Celma, A., Manuel, G. G., Miró, B., Servian, P., & Abascal, J. M. (2024). Effect of 5-Alpha Reductase Inhibitors on Magnetic Resonance Imaging and Prostate Cancer Detection. Biomolecules, 14(2), 193. https://doi.org/10.3390/biom14020193
Vancouver
Morote J, Picola N, Muñoz-Rodriguez J, Paesano N, Ruiz-Plazas X, Muñoz-Rivero MV, et al. Effect of 5-Alpha Reductase Inhibitors on Magnetic Resonance Imaging and Prostate Cancer Detection. Biomolecules. 2024;14(2):193. doi:10.3390/biom14020193
BibTeX
@article{Morote2024,
author = {Morote, Juan and Picola, Natàlia and Muñoz-Rodriguez, Jesús and Paesano, Nahuel and Ruiz-Plazas, Xavier and Muñoz-Rivero, Marta V and Celma, Ana and Manuel, Gemma García-de and Miró, Berta and Servian, Pol and Abascal, José M},
title = {Effect of 5-Alpha Reductase Inhibitors on Magnetic Resonance Imaging and Prostate Cancer Detection},
journal = {Biomolecules},
year = {2024},
volume = {14},
number = {2},
pages = {193},
doi = {10.3390/biom14020193}
}
EUVIMED